Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPT60621
- Development stage
- Discontinued
- Lead developer
- Coeptis Pharmaceuticals
- Administration
- Oral
01
Overview
CPT60621 is a clinical-stage drug candidate being developed by Coeptis Therapeutics. It is under investigation primarily for the treatment of neoplasms, including Parkinson's disease and potentially other cancers[3][4][9]. The precise mechanism of action, molecular target, modality, and detailed pharmacological information have not been disclosed in public sources as of this time[4]. The development status is at the clinical stage, but the highest phase reached in human trials is not published. Coeptis Therapeutics’ strategy focuses on advancing novel therapies in oncology and related diseases.
- Other names
- CPT-60621CPT60621CPT 60621
Beyond the preview
Go deeper on CPT60621.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPT60621.